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The Studs of Tamo\i len and Raloxifene STARt is designed to
determine ss hether the druc used to treat and prevent osteoporosis.
raloxitene Evistacs) is as eIlecti e as tanioxiten (\ovaldexhi) in
reducing breast cancer in women who are at the greatest risk for the
disease. The study has a five-year recruitment plan. which will
enroll 22.000 women nationwide, makine it one of the largest
studies desiizned to find wa\ s to prevent hreast cancer. The stud\
opened in liar au at the Unis ersity of Hawaii’s Cancer Research
Center of Hawaii in July ol I 003. The STAR Study has since
recruited 114 of Ha\\ ai i’s wonieri, all of whom has e an increased
risk of developing breast cancer.
Tamoxifen was shown to red nec the chance of des eloping inva
sive breast cancer h —PY/2 in the Breast Cancer Prevention Trial
I BCPT. a study ofos er 13.000 premenopausal and postmenopansal
ss omen at high risk of breast cancer. in the BCPT. half the ss omen
took tanioxifen and half took a placebo an inactive pill that looked
like tamoxiten Participants taking ianioxifen also had fewer frac
tures of the hip. wrist, and spine than women taking the placebo
Data regarding breast cancer incidence and raloxifene were ob
tained from the Multiple Outcomes of Raloxifene Evaluation
(MORE) trial. The MOREtrial was a multi—centerosteoporosis trial
that invols ed 7.705 postmenopausal \s omen with osteoporosis
entered at centers ai’ound the world. Vs omen were randomized to
ccci \:e either ralox i fcite at (9) or 1 21) nmr/d a’ placeh . The 45 month
results from the MORE trial shoss ed a reduction in ins asive breast
cancer by 7Y) in women who took raloxilene daily lbr four years,
It is important to recognize that this study was designed as an
osteoporosis ‘tudy. Women ssere selected because of their pie-
existing osteoporosis. Breast cancer risk ss as not considered. These
results emphasize the alue of the STAR ss hich srill compare the
\s orth ot raloxi fene in ss omen at increased risk for the disease. and
ill compare this ss ith tamoxiten in a randomized clinical trial in
which breast cancer incidence is a primary study end point.
While tamoxifen has been shown to reduce breast cancer risk in
high risk ssomen, the drug increased the women’s chances of
developing four potential l\ lit’e—threatening health problems: uter
ine cancer, deep vein thrombosis. pulmonar\ embolism, and possi—
bE stroke. Women taking tamo\ifen ha\ e a tss o— to three—fold
increased risk of uterine cancer, While pres ions data indicated that
tanioxifen increased the risk of only endomctrial cancer. recent case
studies suggest that tamoxifen ma also slightly increase the risk tor
uterme sarcoina. In the BCPT there are about two eases of uterine
sarcoma per 10.00(1 women taking tamoxifen each vear’. Risk br
ascular events are similar to those seen with hornione replacement
therapy ( HRT
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Information about the safet of ralosilene i limited compared t
the data a ailable on tamoxilen. Raloxitene s as appro\cd in
December 1007 by the FDA to prevent osteoporosis and has been in
clinical trials for about five ears. Tainoxilen has been approved bx
the FDA to treat women with breast cancer for more than 2() years
and has been in clinical trials for about 30 years. Women taking
raloxi fene m studies f osteopL rosi s ha\ e had an increased chance
at dc\eloping a deep vcm thrombosis or prilimnai’ enibohsin
similar to the risk seen ‘ ith tamoxifen. In these studies. ralax1ene
did not increase the risk of endometrial cancer. An inportant
objective of STAR will he to compare the long—term safet ot
raloxifene and tamoxifen in s omen at increased risk (or breast
cancer.
omen who participate in STAR must he pos tnlenopansal. at
least age 35. and ha e an increased risk of breast cancer as deter
mined by their age, family histor\ of breast cancer. personal medical
history, age at first menstrual period, and age at first live birth. They
will also go through a process known as intormed consent. during
which the will learn about the potential benetit and risks of
tanoxifen and raloxifene befoie deciding hether to participate ni
STAR. Information sessions for STAR are held monthl\ at the
Cancer Research Center of Hawaii,
Once a woman chooses to participate. she will he randomly
assigned to receive either 2() mg tamoxifen or6() mg ralox i fene dai lv
for li\e \ears. She ill he seen at the (‘ancer Research Center hr
follo —rip evcr six months ..At that time she s ill he interviewed
regarding her health status and may also recei e a clinical breast
exam which is required every six months. Each
woman will continue her health care with her
regular physicians Annual mammogranis and
lab tests to include CBC and liver and kidne
function studies are required. Pelvic exams vill
be required annuall for all v omen with the
exception of those who have had a total hyster
ectonmy and hi lateral oophorectomv Study drugs
are provided without charge and a six months’
supply v ill he given at the time of the follow—up
visit. Throughout her participation. a \\ oilman
will he closel rrionitored for any adverse events.
and updated regarding any new findings.
The STAR presents an important option for
women at high risk I or breast cancer. Tanioxifen
has been approved for this indication. Jn the
recent ‘‘American Societ of Clinical Oncology
Technology Assessment on Breast Cancer Risk
Reduction Strategies: Tamoxifen and
Raloxifene”. it is stated, “It is premature to
recommend raloxifcnc ue to lo er the ri’k ol
developing breast cancer outside of a clinical
trial setting.’’
STAR is now into its Iourth year with more
than 60c4 of accrual achieved. Please consider
this important trial hen counseling s omen
who are at high risk fr breast cancer.
The L miis ersitv of Hawaii’s (‘ancer Research
Center of Haw an is one of more that 400 sites
participating in STAR, Dr. Nancy Furumoto is
the Principal In estigator: Ann Kelminsk i. RN. is Program Coordi—
ilator.
F-or more intarmanon about STAR. or to ieferpatients please call
the Cancer Research (‘enter at I S t56-2979 or isit the National
Surgical Adjuvant Breast and Bowel Project (NSABP) web site at
bEg w ns ikppil( Ldjf the \( I Llink ml tn us web situ it fefl —
emnsLmtit ils urn nih ..os urthL ( mrta R.sm. nruh ( Lntci at H os a
web site at w \\ w.creh.aruu.
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